GERN

Geron Stock Price

1.29
0.00 (0.0%)
Upgrade to Real-Time
Regular Market
1.29

Low
1.22

52 Week Range

High
2.65

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Geron Corp GERN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 1.29 10:39:38
Open Price Low Price High Price Close Price Prev Close
1.30 1.27 1.32 1.29
Bid Price Ask Price Spread News
1.29 1.30 0.01 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
900 335,900 $ 1.29 $ 433,377 - 1.22 - 2.65
Last Trade Time Type Quantity Stock Price Currency
10:39:50 20 $ 1.2976 USD

Period:

Draw Mode:

Geron Corp Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 412.54M 318.57M 316.40M $ 253.00k $ - -0.28 -4.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 502.55k 1.60%

more financials information »

Geron News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical GERN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.251.361.221.291,883,8230.043.2%
1 Month1.521.541.221.382,830,780-0.23-15.13%
3 Months1.482.231.221.718,893,292-0.19-12.84%
6 Months1.712.3551.221.746,097,486-0.42-24.56%
1 Year1.882.651.221.764,351,127-0.59-31.38%
3 Years3.486.990.752.103,540,069-2.19-62.93%
5 Years2.636.990.752.473,140,364-1.34-50.95%

Geron Description

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug.


Your Recent History
NASDAQ
GERN
Geron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.